Chemoembolisation With CPT11 Loaded DC Bead With Cetuximab and 5FU/LV in First Line in Patients With KRAS Wildtype mCRC
The purpose of this study is to assess feasibility of chemoembolization with DC Bead loaded with Irinotecan in combination with Cetuximab and 5FU/LV as a first line treatment for wildtype KRAS unresectable liver metastases from colorectal cancer.
Liver Metastases|Colorectal Cancer
DEVICE: DC Beadâ„¢|DRUG: Cetuximab|DRUG: 5 FU|DRUG: Irinotecan
Feasibility of chemoembolization with DC Bead loaded with Irinotecan, Feasibility of the study by measuring the number of enrolled patients who can finish the first cycle of treatment, after one cycle = after 8 weeks
progression-free survival, progression-free survival, From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 18 months
20 patients will be included. The duration of the trial will be approximately 24 months.

Every 8 weeks there will be a tumour lesion assessment.